Free shipping on all orders over $ 500


Cat. No. M1754
WP1130 Structure


Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
5mg USD 72 In stock
10mg USD 128 In stock
50mg USD 498 In stock
100mg USD 840 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

WP1130 is a cell-permeable tyrphostin compound that acts as a partially selective deubiquitinase (DUB) inhibitor and suppresses JAK-Stat signaling pathway. Reported to cause accumulation of polyubiquitinated p53, JAK2 and Bcr-Abl, and reduce c-Myc and MCL-1 protein levels in several tumor cells and downregulate Stat3 and NF-κB activities (IC50 <1 µM in MCL cells) leading to tumor cell apoptosis (IC50 ~1.2 µM in Z138 cells). Suggested to modify active site cysteine of DUB and inhibit USP5, UCH-L1, USP9x, USP14, and UCH37 activities (≥80% inhibition at 5 µM) without affecting 20S proteasome. Reported to exert stronger antiproliferative and antitumor properties than STAT3 Inhibitor III, WP1066 in xenograft mouse models of CML and melanoma.

Customer Product Validations & Biological Datas
Source Cancer Res (2010). Figure 1. WP1130
Method immunoblotting
Cell Lines HEK293T cells
Concentrations 5 μmol/L
Incubation Time 2 h
Results WP1130 displayed potent antiproliferative properties against various other tumor cell lines of myeloid and lymphoid origin as well as HEK293T cells
Cell Experiment
Cell lines CML cells
Preparation method MTT (viability) assay CML cells were seeded in 96-well plates (2*104 cells/well) and WP1130, imatinib mesylate, or dasatinib (0.08-10 µ M) were added in a final volume of 100 µL medium. Plates were incubated at 37°C for 72 hours, after which 20 µL of 3-4,5-dimethylthiazolyl-2-2, 5-diphenyltetrazolium bromide (MTT) reagent (Sigma; stock 5 mg/mL) was added, and the plates were incubated at 37°C for another 2 hours. Cells were lysed with 100 L lysis buffer (20% sodium dodecyl sulfate [SDS] in 50% N, N-dimethylformamide adjusted to pH 4.7 with 80% acetic acid and 1 M hydrochloric acid; final concentration of acetic acid was 2.5% and hydrochloric acid was 2.5%) and incubated for 6 hours. The optical density of each sample at 570 nm was determined with a SPECTRA MAX M2 plate reader (Molecular Devices, Sunnyvale, CA).
Concentrations 0.08-10 µ M
Incubation time 72 h
Animal Experiment
Animal models CML tumors and Bcr/Abl-expressing cells in nude mice
Formulation a 0.1-mL suspension of 1:1 dimethylsulfoxide to polyethylene glycol 300
Dosages 30 mg/kg every other day for 5 injections
Administration injected intraperitoneally
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 384.3
Formula C19H18BrN3O
CAS Number 856243-80-6
Purity 98.94%
Solubility DMSO 67 mg/mL
Storage at -20°C

Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response.
Perry JW et al. PLoS Pathog. 2012 Jul;8(7):e1002783. PMID: 22792064.

A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination.
Kapuria V et al. Cell Signal. 2011 Dec;23(12):2076-85. PMID: 21855629.

Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.
Kapuria V et al. Cancer Res. 2010 Nov 15;70(22):9265-76. PMID: 21045142.

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
Bartholomeusz GA et al. Blood. 2007 Apr 15;109(8):3470-8. PMID: 17202319.

Related JAK Products

Peficitinib (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.


FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM.


WHI-P97 is a JAK3 inhibitor with an estimated Ki value of 0.09 microM from modeling studies and a measured IC50 value of 2.5 microM in EGFR kinase inhibition assays.


SAR-20347 is a potent dual inhibitor of JAK1 and TYK2 with IC50 values of 23 and 0.6 nM, respectively.


Itacitinib, also known as INCB39110 or INCB039110, is a potent JAK1 tyrosine kinase inhibitor.

Abmole Inhibitor Catalog 2017

Keywords: WP1130, Degrasyn supplier, JAK, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.